Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Aug;2(4):356-61.
doi: 10.1007/s11906-000-0038-7.

Prehypertension: a possible target for antihypertensive medication

Affiliations
Review

Prehypertension: a possible target for antihypertensive medication

S D Nesbitt et al. Curr Hypertens Rep. 2000 Aug.

Abstract

Vascular changes associated with elevated blood pressure may precede the clinical diagnosis of hypertension. Even after the diagnosis is made, associated coronary heart disease and renal disease continue to progress, despite adequate blood pressure control. Early treatment of blood pressure may reduce the incidence of clinical hypertension and reduce the long-term consequences of hypertension. Animal studies have shown that early blood pressure lowering, through blockade of the renin-angiotensin system, prevents long-term hypertension. Prevention is an important goal in the treatment of hypertension. Our best attempts to prevent hypertension use nonpharmacologic methods of diet and exercise. These methods are fraught with difficulties of implementation and compliance that limit their success. Finding novel approaches to prevent hypertension may have a major impact on the incidence of hypertension. We are investigating the effect of 2 years of treatment with an angiotensin receptor blocker (candesartan cilexitil) compared with placebo, followed by 2 years of follow-up, on the incidence of hypertension in patients with high-normal blood pressure. Incidence of hypertension after discontinuation of active treatment will be compared with the incidence in the placebo group. There will be 1000 patients enrolled in the study, which will be completed in 2004.

PubMed Disclaimer

References

    1. Can J Physiol Pharmacol. 1987 Apr;65(4):573-8 - PubMed
    1. N Engl J Med. 1977 Feb 24;296(8):405-11 - PubMed
    1. J Hypertens Suppl. 1989 Dec;7(6):S52-5 - PubMed
    1. J Chronic Dis. 1971 Mar;23(10):723-54 - PubMed
    1. Clin Exp Hypertens A. 1985;7(2-3):243-55 - PubMed

MeSH terms

LinkOut - more resources